Se destacan algunos párrafos que muestran lo que están en vía de aportar a las terapias celulares y el status de su proyecto PRS ®, biomedicamento inmunomodulador y antiinflamatorio
Read moreUn 80% de pacientes con tumores neuroendocrinos responden al tratamiento con Lutatera y se ha comprobado que en muchos casos los tumores reducen su tamaño y en otros se estabilizan y mejoran los sín...
Read moreHan demostrado que gracias a la combinación entre la cirugía robótica y la sonda SENSEI® la técnica del ganglio centinela en cáncer de próstata, que es considerada una técnica compleja, es fia...
Read moreIBEC researcher Javier Ramón Azcón has been awarded an “ERC Proof of Concept Grant.” This prestigious funding is granted by the European Research Council to explore the commercial and societal p...
Read moreSparingVision today announces that it has selected a second target as part of its strategic collaboration with Intellia Therapeutics, Inc.to develop novel genomic medicines utilizing CRISPR-based gene...
Read moreThe eleven accelerated companies in the BCN Health Booster raised €16.4 M of private capital, and €35.4 M of public funding during 2022, the first year of the programme’s launch, a period in whi...
Read moreThe MAF-TEST® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosp...
Read moreThe basque Biopharmaceutical company is positioned as the main national distributor of bioreagents thanka to its constant expansion of represented brands.
Read moreADmit Therapeutics is a biotechnology company founded at the end of 2017 as a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL). The company is focused on the development and commerc...
Read moreThe journal Science Translational Medicine has published the results of a preclinical study carried out on rodents that shows the efficacy of uric acid in improving the prognosis of ischaemic stroke. ...
Read moreAM-Pharma B.V. today announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacemen...
Read moreSpark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy targeting an undisclosed inherited retinal dis...
Read more